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exon 20 (Y764), and four types of substitution mutation in exon 18 
(E697K), 19 (S754F, D761N), and 21 (L858R). L858R in exon 21 
found in 5 of 10 tumor tissues with mutations was the most frequent 
mutation of EGFR. EGFR mutations were associated with favor-
able response (8 of 10 vs 3 of 20, P = 0.001), signiﬁcantly prolonged 
progression-free survival (PFS; median, 14.0 vs 3.6 month, P = 0.0319) 
and overall survival (OS; median, 17.0 vs 9.2 month, P = 0.0267). 
K-ras Mutations found in 4 patients were the same type: change of G 
to T at the ﬁrst base of codon12 leading to the amino change of glycine 
to cysteine (G12C). K-ras mutations were associated with progressive 
disease, signiﬁcantly decreased PFS (median, 2.5 vs 7.5 month, P = 
0.0108) and OS (median, 5.2 vs 16.3 month, P = 0.007). Only 1 patient 
harbored both EGFR and K-ras mutations. The response rate in EGFR 
mt(+)/K-ras mt(-), EGFR mt(-)/K-ras mt(-), and EGFR mt(-)/K-ras 
mt(+) were 88.9%, 17.6% and 0%, respectively (P<0.001). Interclass 
comparison for response rate: EGFR mt(+)/K-ras mt(-) and EGFR mt(-
)/K-ras mt(-), EGFR mt(+)/K-ras mt(-) and EGFR mt(-)/K-ras mt(+) 
reached statistical signiﬁcance (P =0.001 and P = 0.018, respectively), 
whereas EGFR mt(-)/K-ras mt(-) and EGFR mt(-)/K-ras mt(+) didn’t(P 
= 1.000). The progressive disease rate in EGFR mt(-)/K-ras mt(-) and 
EGFR mt(-)/K-ras mt(+) were 17.6% and 66.7%, P = 0.140. 
Conclusions: For NSCLC patients from China, EGFR mutation is 
a very important biomarker to predict beneﬁt from geﬁtinib, and the 
role of K-ras mutation in predicting response to geﬁtinib needs further 
investigation.
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Purpose: This study was designed to evaluate the efﬁcacy and toxic-
ity of erlotinib in patients with advanced non-small cell lung cancer 
(NSCLC) who had progression following treatment with geﬁtinib. 
Methods: The study included stage IIIB/IV recurrent or metastatic 
NSCLC patients who received two or three prior chemotherapy regi-
mens and showed progressive disease within four months of geﬁtinib 
therapy discontinued. Patients received erlotinib 150 mg daily until dis-
ease progression or unacceptable toxicity. EGFR mutations and other 
genetic abnormalities were analyzed from available tumor samples. 
Results: Patient and disease characteristics (n= 21) included median 
age 56 years; number of prior chemotherapy regimens (three, n= 11); 
female (n= 11); adenocarcinoma (n= 15); and never-smoker (n= 11). 
Among the 17 patients with tumor samples available, EGFR mutations 
were detected in 5. The disease control rate (DCR) and response rate 
(RR) for all patients were 28.6% and 9.5%, respectively. The median 
duration of disease control was 125 days. The median time to pro-
gression and overall survival was 60 days and 158 days, respectively. 
Patients who had stable disease (SD) on geﬁtinib showed signiﬁcantly 
higher DCR (75% vs. 17.6% in non-SD patients, P= 0.050) and RR 
(50.0% vs. 0% in non-SD patients, P= 0.029). Among 17 patients with 
biomarker results available, those lacking EGFR mutations who had 
SD on geﬁtinib showed signiﬁcantly higher DCR and RR.
Conclusions: Erlotinib seems to be a potential therapeutic option for 
the treatment of wild-type EGFR, advanced NSCLC patients who had 
SD on geﬁtinib. 
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Background: Single-agent chemotherapy has been considered as 
standard treatment for elderly patients with non-small cell lung cancer 
(NSCLC). However recent subset analyses suggest that platinum-based 
combination chemotherapy may be safely administered to the elderly 
with good performance status (PS). We evaluated the efﬁcacy and 
safety of cisplatin and docetaxel in a phase II study of elderly patients 
aged 70 years or older. 
Methods: Chemotherapy-naive patients aged >70 years with advanced 
NSCLC (IIIB-IV), ECOG performance status (PS) of 0 or 1, a mea-
surable lesion, and adequate organ functions were enrolled. Patients 
received cisplatin (75 mg/m2) and docetaxel (75 mg/m2) administered 
on day 1 every 3 weeks. The primary endpoint was response rate (RR). 
Results: Between October 2004 and September 2006, 26 elderly 
patients with NSCLC were enrolled in the study and all patients were 
treated. Demographics: M/F 17/9; PS 0/1 2/24; median age 75 (range 
70-84). Median number of treatment cycles was 4. Responses in the 26 
evaluable patients included 1CR; 12PR; 7SD; for an objective RR of 
50% (95% CI 31-69%) and a disease control rate of 77%. Median sur-
vival period and 1-year survival rate have not yet been reached. Grade 
3/4 hematologic toxicities included neutropenia (86%), thrombocytope-
nia (5%) and anemia (5%). Non-hematologic toxicities were mild with 
no grade 4 toxicities; grade 3 nausea (9%), anorexia (23%), diarrhea 
(14%), fatigue (9%), allergic reaction (9%) and infection (18%) were 
observed. 
Conclusions: The combination of cisplatin and docetaxel was safe and 
promising for the treatment of chemotherapy-naive elderly patients 
with advanced NSCLC. This regimen warrants further evaluation in a 
phase III trial.
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Background: The aim of this work was to study the association of 
epidermal growth factor receptor (EGFR) mutations and response to 
conventional cytotoxic chemotherapy agents and tyrosine kinase inhibi-
tors (TKIs) in non-small-cell lung cancer patients of Caucasian origin 
since conclusive data have not yet been published. 
